Comparison of the effect of rapamycin and FK506 on release of prostacyclin and endothelin in vitro

Randall W. Yatscoff*, Jon Fryer, James A. Thliveris

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

41 Scopus citations


Alterations in mesangial and endothelial cell production of vasoactive substances may be a contributing factor to the decreased renal blood flow and glomerular thrombosis associated with FK506 nephrotoxicity. In preliminary studies Rapamycin (RAPA) appears to induce fewer renal side-effects than FK506, although further documentation is required. In this study, the effects of FK506 and RAPA on release of prostacyclin, a vasodilator, and endothelin, a vasoconstrictor, were investigated in cultured rabbit mesangial and endothelial cells. In general, the effects of both RAPA and FK506 on the basal or stimulated release of prostacyclin (as measured by release of its stable metabolite, 6-keto-PGF) or endothelin from mesangial cells and endothelial cells were similar with the following exceptions: RAPA resulted in a significant (p < 0.05) increase in the release of prostacyclin (PGI2) from the endothelial cells, while in contrast, FK506 resulted in a significant decrease in the release of this analyte from these cells. The similar effects both drugs have on release of vasodilatory and vasoconstrictor substances in vitro does not explain the differences in renal side-effects of the drugs in vivo.

Original languageEnglish (US)
Pages (from-to)409-414
Number of pages6
JournalClinical Biochemistry
Issue number5
StatePublished - Oct 1993


  • FK506
  • endothelin
  • prostacyclin
  • rapamycin

ASJC Scopus subject areas

  • Clinical Biochemistry


Dive into the research topics of 'Comparison of the effect of rapamycin and FK506 on release of prostacyclin and endothelin in vitro'. Together they form a unique fingerprint.

Cite this